JAMES W NEEL MD NPI 1447232772

NPI Details

James W Neel, MD is a medical oncology internal medicine in Melbourne, FL with 31 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. James W Neel, MD NPI is 1447232772. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF MIAMI, LM MILLER SCHOOL OF MEDICINE
Graduation Year:1995

The provider's business location address is:

1130 HICKORY ST
MELBOURNE, FL
ZIP 32901-973
Phone: (321) 361-5598
Fax: (321) 724-4324

The NPI 1447232772 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (HCPCS:J0129)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Collection of blood sample from implanted device (HCPCS:36591)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Red blood cells, leukocytes reduced, each unit (HCPCS:P9016)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Transfusion of blood or blood products (HCPCS:36430)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)

The enumeration date for this NPI number is 11/14/2005 and was last updated on 5/17/2024.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.